Pfizer and Allergan to Combine With Joint Value of $160 Billion

Updated on
  • Price is 27% premium to Allergan shares before talks public
  • Read to be CEO, Saunders to be president of new Pfizer Plc

Allergan Shares Recoil in Wake $160 Billion Pfizer Deal

Pfizer Inc. and Allergan Plc agreed to combine in a record $160 billion deal, creating a drugmaking behemoth called Pfizer Plc with products from Viagra to Botox and a low-cost tax base.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.